Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Abstract

Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. The types of adverse events were consistent with those seen in prior studies of ipilimumab; however, the rates of elevated liver-function values were higher and the rates of gastrointestinal events were lower than expected on the basis of prior studies. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00324155.).

Keywords

Affiliated Institutions

• Cliniques Universitaires Saint-Luc BE
• University of Siena IT
• University of Tübingen DE
• Bristol-Myers Squibb (Belgium) BE
• Hospital Clínic de Barcelona ES
• Medical University of Vienna AT
• Christian-Albrechts-Universität zu Kiel DE
• Saint Louis University Hospital US
• Bristol-Myers Squibb (United States) US
• Hôpital Saint-Louis FR
• European Institute of Oncology IT
• Hôpital Lyon Sud FR
• Mid Essex Hospital Services NHS Trust GB
• Institut Gustave Roussy FR
• Angeles Clinic and Research Institute US
• Moffitt Cancer Center US
• Hadassah Medical Center IL
• Hôpital de la Timone FR
• National Health Service GB
• Oncology Specialists US
• Memorial Sloan Kettering Cancer Center US
• Dnipropetrovsk State Medical Academy UA

Related Publications